{
    "clinical_study": {
        "@rank": "72181", 
        "arm_group": [
            {
                "arm_group_label": "3-0-3 titration algorithm", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "2-4-6-8 titration algorithm", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Asia. The aim of the trial is to compare the glycaemic control of\n      Levemir\u00ae (insulin detemir) administered once daily according to two titration algorithms\n      after 20 weeks in subjects with type 2 diabetes inadequately controlled on metformin\n      treatment with or without other anti-diabetic drugs (OADs)."
        }, 
        "brief_title": "A Trial Comparing the Glycaemic Control of Levemir\u00ae Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs)", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed with type 2 diabetes mellitus at least 3 months prior to Visit 1 (week -2)\n\n          -  Treatment with at least 1000 mg metformin per day with/without other OADs at a stable\n             dose (at either the maximal tolerated dose or at least half of the maximum\n             recommended dose according to the package insert) for at least 3 months prior to\n             Visit 1\n\n          -  Insulin-na\u00efve subjects\n\n          -  HbA1c above or equal to 7.5% by central laboratory analysis\n\n          -  Body mass index (BMI) below or equal to 35.0 kg/m^2\n\n        Exclusion Criteria:\n\n          -  Female of child-bearing potential who is pregnant, breast-feeding or intend to become\n             pregnant or is not using adequate contraceptive methods\n\n          -  The receipt of any investigational product within 4 weeks prior to Visit 1\n\n          -  Any contraindication to insulin detemir according to the domestic labelling\n\n          -  Anticipated change of dose of any systemic treatment with products, which in the\n             investigator's opinion could interfere with glucose metabolism (such as systemic\n             corticosteroids, beta-blockers, monoamine oxidase [MAO] inhibitors)\n\n          -  Clinically significant diseases which, in the investigator's opinion, may confound\n             the results of the trial or pose additional risk in administering trial product\n\n          -  Any conditions that the investigator judges would interfere with trial participation\n             or evaluation of the results"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01868542", 
            "org_study_id": "NN304-3994", 
            "secondary_id": "U1111-1132-9267"
        }, 
        "intervention": [
            {
                "arm_group_label": "3-0-3 titration algorithm", 
                "description": "The subjects will have insulin detemir administered once daily. The dose will be titrated twice weekly with changes in dose of +/- 3 units if not on target.", 
                "intervention_name": "insulin detemir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2-4-6-8 titration algorithm", 
                "description": "The subjects will have insulin detemir administered once daily. The dose will be titrated twice weekly with changes in dose of 2, 4, 6, 8 units dependent on FPG (fasting plasma glucose) if not on target.", 
                "intervention_name": "insulin detemir", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin", 
                "Hypoglycemic Agents", 
                "Metformin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 14, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Daejeon", 
                    "country": "Korea, Republic of", 
                    "zip": "330-721"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 20-week, Randomised, Multi-centre, Open-labelled Trial Comparing the Glycaemic Control of Levemir\u00ae Administered Once Daily According to Two Titration Algorithms (3-0-3 Algorithm and 2-4-6-8 Algorithm) After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment in Korea", 
        "overall_contact": {
            "email": "clinicaltrials@novonordisk.com", 
            "last_name": "Novo Nordisk"
        }, 
        "overall_official": {
            "affiliation": "Novo Nordisk Pharma Korea Ltd.", 
            "last_name": "MinJung Kim", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in glycosylated haemoglobin A1c (HbA1c) (%) from baseline", 
            "safety_issue": "No", 
            "time_frame": "Week 0, week 20"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01868542"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in HbA1c", 
                "safety_issue": "No", 
                "time_frame": "Week -2, week 12"
            }, 
            {
                "measure": "Proportion of subjects achieving HbA1c below 7.0%", 
                "safety_issue": "No", 
                "time_frame": "Week 20"
            }, 
            {
                "measure": "Change in fasting plasma glucose from baseline", 
                "safety_issue": "No", 
                "time_frame": "week 0, week 12"
            }, 
            {
                "measure": "Incidence of nocturnal hypoglycaemic episodes (23:00\u221205:59)", 
                "safety_issue": "No", 
                "time_frame": "At 20 weeks of treatment and over 24 hours"
            }, 
            {
                "measure": "Change in fasting plasma glucose from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 20"
            }, 
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "Week 20"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}